Oxford Biomedica (LON:OXB) Hits New 12-Month High – What’s Next?

Oxford Biomedica plc (LON:OXB) hit a new 52-week high during trading on Tuesday . The stock traded as high as GBX 455 ($5.65) and last traded at GBX 444 ($5.51), with a volume of 467163 shares traded. The stock had previously closed at GBX 416 ($5.17).

Oxford Biomedica Stock Performance

The company’s 50-day moving average price is GBX 420.29 and its 200 day moving average price is GBX 388.15. The stock has a market capitalization of £435.14 million, a PE ratio of -286.81 and a beta of 1.09. The company has a debt-to-equity ratio of 154.88, a quick ratio of 1.67 and a current ratio of 2.35.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.